Pulmonary embolism in menopausal hormone therapy: a population-based register study

References

• Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the study of women’s health across the nation. Obstet Gynecol Clin North Am. 2011;38(3):489–501.
   PubMed Web of Science ®Google Scholar
• Ziv-Gal A, Flaws JA. Factors that may influence the experience of hot flushes by healthy Middle-aged women. J Womens Health. 2010;19(10):1905–1914.
   Web of Science ®Google Scholar
• Andrikoula M, Prelevic G. Menopausal hot flushes revisited. Climacteric. 2009;12(1):3–15.
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric. 2007;10(3):197–214.
   PubMed Web of Science ®Google Scholar
• Col NF, Guthrie JR, Politi M, et al. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause. 2009;16(3):453–457.
   PubMed Web of Science ®Google Scholar
• Stearns V, Ullmer L, Lopez JF, et al. Hot flushes. Lancet. 2002;360(9348):1851–1861.
   PubMed Web of Science ®Google Scholar
• Crawford SL. The roles of biologic and nonbiologic factors in cultural differences in vasomotor symptoms measured by surveys. Menopause. 2007;14(4):725–733.
   PubMed Web of Science ®Google Scholar
• MacLennan AHBJ, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes (review). MacLennan AH, BroadbentJL, Lester S, Moore V. 2009. UK: John Wiley & Sons, Ltd.
   Google Scholar
• Neves ECM, Birkhauser M, Samsioe G, et al. EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas. 2015;81(1):88–92.
   PubMed Web of Science ®Google Scholar
• Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14.
   PubMed Web of Science ®Google Scholar
• Bergendal A, Bremme K, Hedenmalm K, et al. Risk factors for venous thromboembolism in pre-and postmenopausal women. Thromb Res. 2012;130(4):596–601.
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. Jama. 2004;292(13):1573–1580. Oct 6
   PubMed Web of Science ®Google Scholar
• Roach RE, Lijfering WM, Helmerhorst FM, et al. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost. 2013;11(1):124–131.
   PubMed Web of Science ®Google Scholar
• Canonico M. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Maturitas. 2015;82(3):304–307.
   PubMed Web of Science ®Google Scholar
• Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277–2286.
   PubMed Web of Science ®Google Scholar
• Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166(7):772–780.
   PubMedGoogle Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the women’s health initiative randomized controlled trial. Jama. 2002;288(3):321–333.
   PubMed Web of Science ®Google Scholar
• Scarabin PY. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen Meta-analysis. Climacteric. 2018;21(4):341–345.
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Lowe GD, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and Meta-analysis. BMJ. 2008;336(7655):1227–1231.
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.
   PubMed Web of Science ®Google Scholar
• Canonico M. Hormone therapy and hemostasis among postmenopausal women: a review. Menopause. 2014;21(7):753–762.
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845.
   PubMed Web of Science ®Google Scholar
• Fritz MA. Clinical gynecologic endocrinology and infertility. Philadelphia, USA: Lippincott Williams & Wilkins, a Wolters Kluwer business; 2011. (8, editor.).
   Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. Jama. 2004;291(14):1701–1712.
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280(7):605–613.
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol. 2010;30(2):340–345.
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Panay N, Pexman-Fieth C. Pexman-Fieth C. Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety. Maturitas. 2013;76(1):10–21.
   PubMed Web of Science ®Google Scholar
• Schneider C, Jick SS, Meier CR. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations. Climacteric. 2009;12(5):445–453.
   PubMed Web of Science ®Google Scholar
• Swedish Society of Obstetrics and Gynecology. SFOG-Råd för menopausal hormonbehandling 2019, uppdaterad version 2021; [cited 2019 Dec 09]. Available from: https://www.sfog.se/media/337273/mht-sfog-raad-210121.pdf.
   Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150.
   PubMed Web of Science ®Google Scholar
• The 2017 hormone therapy position statement of The North American menopause society. Menopause. 2017;24(7):728–753.
   PubMed Web of Science ®Google Scholar
• Mohammed K, Abu Dabrh AM, Benkhadra K, et al. Oral vs transdermal estrogen therapy and vascular events: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(11):4012–4020.
   PubMed Web of Science ®Google Scholar
• Laliberté F, Dea K, Duh MS, et al. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause. 2018;25(11):1297–1305.
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
   PubMed Web of Science ®Google Scholar
• National board of Health and Welfare. Kvalitet och inneha°ll i patientregistret Utskrivningar fra°n slutenva°rden 1964–2007 och besök i specialiserad öppenva°rd (exklusive primärva°rdsbesök) 1997–2007. 2009.
   Google Scholar
• Statistics Sweden. DESCRIPTION OF THE REGISTER Total Population Register. 2016.
   Google Scholar
• World Health Organization. International Classification of Diseases (ICD) Information Sheet; [cited 2020 May 18]. Available from: https://www.who.int/classifications/icd/factsheet/en/.
   Google Scholar
• World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)-WHO Version for; 2019; [cited 2020 May 18]. Available from: https://icd.who.int/browse10/2019/en#/I26.
   Google Scholar
• Brooke HL, Talback M, Hornblad J, et al. The swedish cause of death register. Eur J Epidemiol. 2017;32(9):765–773.
   PubMed Web of Science ®Google Scholar
• Wettermark B, Hammar N, Fored CM, et al. The new swedish prescribed drug register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–735.
   PubMed Web of Science ®Google Scholar
• The Riksdag. The Act concerning the Ethical Review of Research Involving Humans (SFS 2003:460) Stockholm: The Riksdag; [cited 2017 Oct 11]. Available from: https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/lag-2003460-om-etikprovning-av-forskning-som_sfs-2003-460.
   Google Scholar
• Sveriges Riksdag. Offentlighets- och sekretesslag (2009:400) 2009; [cited 2019 Jun 3]. Available from: https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/offentlighets–och-sekretesslag-2009400_sfs-2009-400.
   Google Scholar